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Abstract  
The high prevalence of smoking in people with serious mental illness contributes 
substantially to the disproportionately high morbidity and premature mortality in this 
population. There is an urgent need to help people with serious mental illness to quit 
smoking. We discuss competing explanations for the high prevalence of smoking in people 
with serious mental illness and the effectiveness of available smoking cessation interventions. 
We propose trials of harm reduction options, such as nicotine replacement therapy and 
electronic cigarettes (e-cigarettes), as long-term substitutes for cigarettes in smokers with 
serious mental illness who are unable to quit smoking. We also propose that smoke-free 
psychiatric units provide smoking cessation support on patient admission to the hospital and 
after discharge. 
Key messages 
• Reducing the prevalence of smoking among people with serious mental illness is vital 
to decreasing the health inequities faced by this population. 
• Smoking bans in psychiatric facilities should be encouraged and enforced with the 
provision of smoking cessation support, such as nicotine replacement therapy and 
counselling. 
• Innovative approaches such as internet and mobile phone-based smoking cessation 
interventions should be trialled as they could improve access of smokers with serious mental 
illness to smoking cessation support. 
• Tobacco harm reduction options such as e-cigarettes should be evaluated in smokers 
with serious mental illness who are not able to quit with standard cessation approaches. 
 
  
Introduction 
Serious mental illnesses include diagnosable mental, behavioural , or emotional disorders that 
cause serious functional impairment and substantially interfere with or limit one or more 
major life activities.
1
 The prevalence of cigarette smoking in people with serious mental 
illnesses such as schizophrenia, schizoaﬀective disorders, bipolar disorder, and major 
depression, is much higher than in the general population.
2,3
 The association of smoking with 
serious mental illness is strongest and most consistent in people with schizophrenia, who are 
three to seven times more likely to smoke compared with the general population.
4,5
 Those 
with bipolar disorder are three to four times more likely
6
 and those with major depression are 
twice as likely to smoke,
7 
compared with people without these disorders. Tobacco smoking is 
a major contributor to high premature mortality and severe morbidity in people with serious 
mental illness.
2
 The combination of heavy daily smoking, limited access to quality health 
care, and dyslipidaemia produced by some antipsychotic medication, increases the risk of 
cancers and heart disease and reduces life expectancy by 10 to 15 years in this population.
8–10
 
Serious mental illness is also associated with dependence on alcohol and other substances, 
such as cannabis and cocaine,11 which further compounds the risk of adverse health 
outcomes.
12–15
 
What should be done to reduce smoking in people with serious mental illnesses? The answer 
depends on responses to the following questions. What factors drive the high prevalence of 
smoking in this population? How easy or diﬃcult is it for people with serious mental illness 
to quit smoking? Are smoke-free psychiatric facilities an appropriate policy response? Should 
we consider tobacco harm reduction—i.e., encouraging heavy smokers with serious mental 
illness to use non-smoked nicotine products, such as electronic cigarettes (e-cigarettes), 
instead of smoking tobacco? 
 Smoking in serious mental illness: cause or eﬀect?  
There are several hypotheses about the high smoking prevalence in people with serious 
mental illness, especially schizophrenia and major depression. These hypotheses are based on 
the following premises: that serious   mental illness causes smoking (self-medication 
hypothesis);
16,17 
that smoking causes serious mental illness (causal hypothesis);
18
 or that both 
smoking and serious mental illness result from a common cause (shared vulnerability 
hypothesis).
19,20 
A summary of evidence for and against each of these hypotheses is presented 
in table 1.  
There is no single unifying hypothesis that fully explains the relationship between smoking 
and all serious mental illness. For schizophrenia and major depression, the self- medication 
hypothesis is most widely accepted in clinical settings, where it might encourage permissive 
attitudes towards smoking in people with serious mental illnesses. However, the 
epidemiological evidence for the self- medication hypothesis in schizophrenia is weak (table 
1). A large proportion of people with schizophrenia start smoking before the symptoms of the 
disease appear, and smokers with schizophrenia do not develop psychosis on stopping 
smoking.
35,53,54 
Nicotine does not have anti- psychotic properties, and antipsychotics do not 
aid in smoking cessation.
34,55 
The self-medication hypothesis has a stronger evidence base in 
major depression (table 1).
56
 Similarly, the other hypotheses also require stronger 
longitudinal and biological evidence to assess their validity. These three hypotheses have 
diﬀerent implications for policies to reduce cigarette smoking in people   with serious mental 
illness. The self-medication and shared vulnerability hypotheses could favour more lenient 
policies, such as tobacco harm reduction, as an alternative to cigarette smoking in this 
population. The causal hypothesis could justify an intensiﬁcation of eﬀorts to discourage 
smoking in people with serious mental illness (e.g., hospital smoking bans), with the aim of 
encouraging abstinence from all forms of nicotine consumption. Evidence for causality 
should be judged individually for diﬀerent mental illnesses when deciding on these tobacco 
control policies. 
Smoking cessation in people with serious mental illness 
Smoking uptake is increased and cessation rates are decreased in people with serious mental 
illness.
6,57
 People with serious mental illness who smoke are also often heavily dependent on 
nicotine
58
 and experience more severe withdrawal symptoms when they stop smoking than do 
people without serious mental illness.
59
 Co- existing alcohol and substance abuse might 
reinforce the rush or buzz that smokers receive from nicotine consumption,  making  quitting  
even  more  diﬃcult for those with multiple dependence diagnoses.14,60 Despite these barriers, 
people with serious mental illness report that they are as motivated to stop smoking as people 
without serious mental illness.
61
 The low cessation rate among people with serious mental 
illness has been attributed to a combination of a failure to promote smoking cessation and 
diﬃculty of access to smoking cessation services.9,62,63 
Smokers with serious mental illness, like all smokers, can improve their physical and mental 
health by quitting.
25
 However, many of these smokers, and the mental health professionals 
who care for them, believe that their mental health will worsen if they quit smoking.
62
 For 
this reason, mental health professionals might not encourage attempts to quit.
62
 This belief is 
inconsistent with the evidence that smoking cessation reduces depression, anxiety, and stress 
in people with serious mental illness.
25
 
Smoking cessation guidelines for all smokers, including those with serious mental illness, 
recommend pharmacotherapy in combination with behavioural interventions.
64,65 
The most 
eﬀective pharmacotherapies include nicotine replacement therapy, the atypical antidepressant 
bupropion, and varenicline, a nicotinic receptor partial agonist.
66
 Behavioural interventions 
include brief advice (a short intervention lasting from 
30
 seconds to 3 minutes), ﬁnancial 
incentives for quitting, self-help material, and counselling.
64,65,67
 
Numerous clinical trials in developed countries have shown the eﬀectiveness of smoking 
cessation pharmacotherapies in smokers in the general population.
26,68,69
 However, these 
pharmacotherapies have not been extensively tested in people with serious mental illness.
70
 
Concerns about the side-eﬀects of varenicline and bupropion have prompted caution in the 
use of these drugs in people with serious mental illness. A network meta-analysis of 14
 
randomised clinical trials of smoking cessation pharmacotherapies in smokers with serious 
mental illness found that bupropion and varenicline were both eﬀective (odds ratio 4·51, 95% 
credible interval 1·45–14·04 for bupropion and 5·17, 95% credible interval 1·78–15·06 for 
varenicline) and acceptable.66 However, the evidence base was rated as very low quality.66 
Other studies suggest that nicotine replacement therapy might be eﬀective in reducing 
smoking and maintaining long- term abstinence in smokers with serious mental illness.
71,72
 
Behavioural support for smoking cessation in people with serious mental illness is  eﬀective  
at  long-term (>6 months) follow-up (relative risk 1·35, 95% CI 1·01–1·81).73 So too is 
pharmacotherapy alone or in combination with counselling or motivational inter- viewing.
74–
76
 Mobile phone-based support and internet- assisted cessation is eﬀective in general 
populations, but these interventions have not been well studied in smokers with serious 
mental illness.
77–79
 It is unclear which smoking cessation options are best for people with 
serious mental illness, but the limited evidence suggests that those that are eﬀective for 
smokers in the general population are also eﬀective for smokers with serious mental illness, 
with or without comorbid substance abuse disorders.
75,80
 Abstinence from tobacco might also 
reduce relapse to substance abuse in people with co- morbid mental illness.
80
 
Smoking bans in psychiatric units 
Public bans have reduced the prevalence of smoking in the general population by de-
normalising smoking and making it inconvenient to smoke.
81
 Similar bans have been adopted 
in health-care settings, especially in developed nations such as the UK, the USA, and 
Australia.
82,83 
However, smoking bans in mental health facilities of these countries have been 
slowly and inconsistently implemented.
84–86 
The high prevalence of heavy smoking among 
the patients, fear of patient aggression, and the staﬀ’s sympathy for patients who have been 
denied the opportunity to smoke have probably played a part (panel 1).
86,87
 
Smoking bans in psychiatric inpatient units in Australia
88 
have attracted several criticisms. 
One is that bans in secure psychiatric units are “cruel and inhumane” because they deny the 
right to smoke to patients who are involuntarily detained.
89,90 
For people with serious mental 
illness in long-term residential care, smoking bans can represent enforced smoking cessation 
because smoking is not permitted on the premises and patients cannot leave the facility to 
smoke. This situation raises various ethical concerns but smoking is one of many freedoms 
that people living in these circumstances lose. Critics of smoking bans suggest that patients 
should be allowed to smoke in designated areas, to protect non-smokers while allowing 
smokers with serious mental illness the right to harm only themselves.
91,92
 Those who defend 
smoking bans in mental health facilities argue that designated smoking areas convey the 
message that smoking is acceptable for people with serious mental illness.
93
 
The claim that smoking bans are paternalistic violations of individual freedom that deprive 
patients with serious mental illness of “one of their few remaining pleasures”90,91 implies an 
assumption that smokers with serious mental illness do not want to or cannot quit smoking. 
However, almost as many of these patients want to quit as smokers without mental 
illnesses.
61
 They simply ﬁnd it more diﬃcult to do so because they do not receive adequate 
encouragement or support in quit attempts, and because they spend considerable periods of 
time in a social environment that normalises and reinforces heavy smoking.
94
 
Critics have also blamed smoking bans for acts of violence against staﬀ, often on the basis of 
very weak evidence.
95–97
 These critics place greater weight on rare acts of violence to staﬀ 
and patients than on the far larger harms that smoking causes to patients. Another concern is 
increased toxicity of antipsychotic medications (e.g., clozapine and olanzapine) if people on 
these medications abruptly stop smoking.
98
 In such cases, psychiatrists providing the 
treatment should make appropriate adjustments in drug dosage, monitor the person while an 
inpatient, and arrange for dosage review after discharge, if the person resumes smoking.
98,99
 
Although quitting can be extremely challenging for very heavy smokers with serious mental 
illness, smoking bans can give these patients a chance to quit in the most favourable setting, 
without an opportunity to smoke, and with good access to medications and psychological 
support from health-care professionals to manage their withdrawal symptoms.
87 
These 
advantages might be partially oﬀset if bans deter smoking patients from seeking treatment, 
although it remains to be seen how commonly this problem occurs.
95
 
Smoking bans alone will not produce long-term abstinence.
100
 A humane policy would 
provide patients with access to nicotine while in hospital—e.g., by providing nicotine 
replacement therapy, counselling, and other pharmacotherapy on admission. Cessation 
support should also be provided at discharge and on return to the community.
101
 This 
approach has encouraged attempts to quit in patients discharged from a smoke-free 
psychiatric hospital.
102
 Government policies that subsidise pharmacotherapies and harm 
reduction options for people with serious mental illness can help to maintain abstinence. 
Training hospital staﬀ in smoking cessation and relapse prevention methods and correcting 
their misapprehensions about the eﬀects of smoking bans could increase compliance with 
smoke-free policies and reduce patients’ distress.84,103 
 
 
Tobacco harm reduction 
The most eﬀective way to eliminate tobacco-related harm is to abstain from using any 
tobacco or nicotine products. This approach has long been the central aim of tobacco control 
policy. But should smokers who are unable to quit, or who take longer to quit, be encouraged 
to try tobacco harm reduction? 
Contemporary public health discourse about tobacco harm reduction is highly polarised, 
especially in the case of e-cigarettes. Opponents argue that e-cigarettes will deter smokers 
from quitting, serve as a gateway to tobacco smoking in adolescents, and re-normalise 
smoking.
104
 These concerns can only be properly assessed after years of observational 
research on the ways in which these products are used by smokers and non-smokers, and their 
eﬀect on smoking rates. 
Opponents of tobacco harm reduction believe that these potential risks are suﬃciently severe 
to warrant pre-emptive bans on the sale of e-cigarettes and they would only allow their use 
for cessation if they are shown to be safe and eﬀective.105 This approach is likely to restrict 
smokers’ access to e-cigarettes produced by the tobacco and pharmaceutical industries, the 
commercial entities best able to meet the large regulatory costs. This policy has been 
implemented in Australia and Canada, and has been advocated elsewhere. In countries that 
have banned the sale of nicotine- containing e-cigarettes (e.g., Argentina, Canada, and 
Australia),
106,107 
it is important to examine how well these devices help heavily addicted 
smokers (such as those with serious mental illness) either to quit all nicotine use or to switch 
to using e-cigarettes as a safer long-term alternative to cigarette smoking. Heavy smokers 
with serious mental illness should be a high priority group for assessing the value of tobacco 
harm reduction approaches, for several reasons (panel 2).
115
 
Nicotine replacement therapy substantially reduces smoking in smokers with serious mental 
illness.
116
 There is insuﬃcient evidence to justify the routine use of other harm reduction 
products but there is enough evidence to justify clinical trials (table 2). For example, results 
of one clinical trial found that e-cigarettes and nicotine patches were equally eﬀective in 
achieving abstinence at 6 months and equally acceptable to smokers taking medications for 
mental illness.
117 
Another trial found that e-cigarettes signiﬁcantly reduced smoking in 
smokers with schizophrenia.
118
 Other trials are underway to test the eﬃcacy and acceptability 
of e-cigarettes for cessation in smokers with serious mental illness (table 2).
119,120
 
E-cigarettes are considerably less harmful than tobacco cigarettes, and could be more 
acceptable than nicotine replacement therapy for both smoking cessation and tobacco harm 
reduction because of their sensory and behavioural similarities to cigarettes.
121–123 
Switching 
to snus has been associated with substantial population health gains in Sweden.
124
 This 
approach has not been tested as a harm reduction option among smokers with serious mental 
illness, but a clinical trial of snus among general population smokers did not ﬁnd it to be 
better than  high- dose nicotine gum.
125
 Sales bans on these products in many developed 
countries such as Australia, New Zealand, and the European Union (apart from Sweden) 
make it diﬃcult to conduct trials of tobacco harm reduction products.126 
There is a strong case for conducting pragmatic clinical trials of tobacco harm reduction in 
smokers with serious mental illness. These should include trials of the use of e-cigarettes both 
for cessation of all nicotine and as a long-term alternative to smoking in those who are unable 
to stop using nicotine without relapsing to smoking. Conducting clinical trials among people 
with serious mental illness can be challenging as their complex health and social needs can 
make recruitment, retention, and monitoring more diﬃcult than trials in general population 
samples.
127 
Additionally, avolition, which is a negative symptom of schizophrenia, can reduce 
interest in quitting and act as an impediment to recruiting and retaining these smokers in 
smoking cessation trials.
61 
However, the extra investment and eﬀort required to develop the 
evidence base for tobacco harm reduction options for this population is warranted given the 
urgent need to reduce smoking among people with serious mental illness. 
Conclusions 
Smoking prevalence is very high among people with serious mental illness. The reasons are 
not wholly clear, but the main hypotheses are self-medication, shared vulnerability due to 
environmental or genetic risk factors, and a possible causal relationship with smoking. These 
factors are not necessarily mutually exclusive; smoking might have positive eﬀects on some 
symptoms of serious mental illness, but at the cost of worsening other symptoms and 
increasing premature mortality and severe morbidity. 
In general, smokers with serious mental illness are as interested in quitting as are smokers 
without mental illness, but they ﬁnd it diﬃcult to quit and remain abstinent.61,75 Often, 
smokers with psychotic illnesses such as schizophrenia experience social isolation and 
stigma.
128 
This social isolation can also contribute to the challenges of recruiting participants 
with schizophrenia for smoking cessation trials from this population, thus potentially 
adversely aﬀecting the power and external validity of these studies.129 We require innovative 
approaches for trial recruitment and improved access of smokers with schizophrenia to 
cessation methods that are eﬀective in the general population.130 Partnering with mental 
health consumer groups and non-government organisations that provide services to people 
with schizophrenia within the community can be a promising way to engage with this 
population  group.
131
 
Often inadequately enforced and questioned for their ethical validity, smoking bans in mental 
health settings could be an opportunity for smokers with serious mental illness to quit. 
Provision of nicotine replacement therapy and other cessation aids during and after periods of 
hospitalisation should be an ethical minimum for the humane care of smokers with serious 
mental illness. Smoking cessation training should be made available for all mental health 
staﬀ. 
Better evidence is needed on whether smoking cessation methods eﬀective in smokers from 
the general population are as eﬀective in people with serious mental illness. The potential 
role of e-cigarettes should be evaluated in smokers with serious mental illness who try and 
fail to quit smoking. We also need more research on the eﬀectiveness of delivering 
interventions through social media and smartphone apps, and on prevention of long-term 
relapse in people with serious mental illness.
132 
 
 
We searched PubMed, Embase, and CINAHL with no date restrictions, using the terms 
“severe mental illness”, “mental disorder”, “psychiatric”, “schizophrenia”, “psychosis”, 
“depression” and “bipolar disorder” alone and in combination with “smoking”, “tobacco”, 
“smoking cessation”, “quit smoking”, “harm reduction”, “tobacco harm reduction”, 
“smoking reduction”, “electronic cigarette”, “e-cigarette”, “vaporiser”, “cannabis”, “snus”, 
“smoking ban” and “smoke free”. Articles were also identified from the authors’ personal 
collections and from references cited in the included articles. Emphasis was placed on 
recent publications. We generated the final reference list on the basis of the articles’ 
relevance to this paper. Preference was given to randomised clinical trials and meta-
analysis of trials of cessation and harm reduction aids, and prospective observational 
studies and meta-analyses of these studies on associations between cigarette smoking and 
serious mental illnesses and effect of smoking bans in psychiatric hospitals. The site 
www.ClinicalTrials.gov was searched using the search terms: smoking AND (“mental 
illness” OR schizophrenia OR depression OR bipolar). Only trials that had their trial 
completion date listed as during or after January 2015 were included in table 2. Trials with 
unknown status were excluded. 
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Table 1 Hypotheses for the relationship between serious mental illness and smoking 
 Examples of Evidence for Hypothesis Examples of Evidence against Hypothesis 
Self-medication hypothesis 
Major Depression 
 
 
 
 
 
 
 
 
 
 
 
 
Schizophrenia 
 
 Nicotine stimulates nicotinic acetylcholine receptors 
which enhance cognition and improve attention, memory, 
and mood.
21
 
 Monoamine oxidase inhibitors in cigarette smoke may 
have and antidepressant effect by inhibiting the 
breakdown of dopamine and serotonin.
22
 
 People with depression experience stronger withdrawal 
symptoms and negative affect on stopping smoking and 
smoking cessation can result in relapse to depression.
7,23
 
 Some antidepressants (bupropion and nortriptyline) are 
effective for smoking cessation.
23,24
 
 
 Depressed mood is common in persons with 
schizophrenia; so any antidepressant effects of smoking 
are relevant to schizophrenia.
27
 
 
 Nicotine activates α7 nicotinic acetylcholine receptors, 
which increases the release of GABA and decreases the 
release of glutamate. These actions improve attention in 
people who experience deficits in filtering responses to 
sensory stimuli.22,28 
 Nicotine improves other sensory gating deficits, such as 
prepulse inhibition deficit and mismatch negativity, 
potentially improving startle responses and memory 
processing.28–30 
 Smoking relieves antipsychotic medication side-effects, 
such as parkinsonian 
 
 Evidence demonstrates longer term improvement 
in depression and anxiety symptoms after 
smoking cessation.
25
 
 Most antidepressant drugs do not assist smoking 
cessation.
26
 
 
 
 
 
 
 
 
 Smoking often begins before symptoms of 
schizophrenia appear.
33
 
 Nicotine does not have antipsychotic 
properties and treatment with antipsychotics 
 does not aid in smoking cessation.34,35 
 
 
 
 
 
 
 
 
 
 
 
 Causal Hypothesis 
Major Depression 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schizophrenia 
 
 Epidemiological evidence indicates that cigarette 
smoking is associated with an increased risk of 
depression.
36,37
 
 A meta-analysis of 26 studies reported that 
smoking cessation is associated with reductions in 
severity of depression and anxiety symptoms.
25 
Cigarette smoking lowers serotonin function in the 
hippocampus, which can result in depression.
38
 
 
 
 
 
 
 
 Nicotine increases dopamine release in the brain’s 
reward system.
41
 This is consistent with the 
hypothesis that psychotic symptoms are the result 
of increased levels of striatal dopamine.
42
 
 A meta-analysis of epidemiological studies shows 
that smoking often precedes the onset of psychotic 
symptoms, people with psychotic symptoms are 
heaver smokers than those without, and these 
associations persist after controlling for potential 
confounders.
18
 
 The odds of developing major depression in 
daily smokers are lower than the odds of 
individuals with major depression starting 
daily smoking. However, this association 
could be confounded by history of alcohol 
use.
39
 
 A Mendelian randomisation meta-analysis 
discounted a causal relation between 
smoking and major depression as no 
association was reported between a genetic 
marker for nicotine dependence (CHRNA5-
A3-B4 variant) and major depression.
40
 
 
 
 There are few prospective studies testing 
this hypothesis;
18
 stronger longitudinal 
evidence and biological links are needed to 
establish a link between nicotine use and 
psychosis onset.
43
 The association between 
smoking and psychosis could be 
confounded by the association between 
tobacco smoking and cannabis use.
44 
Cannabis use is associated with early onset 
of psychosis, has a dose-response 
relationship with psychosis risk,
43 
and can 
produce psychotic symptoms in people with 
and without psychoses.
45
 Only half of the 
prospective studies in the metanalysis of 
tobacco use measured cannabis use.
18
 
 
  
Shared vulnerability: 
Major Depression 
 
 
 
 
 
Schizophrenia 
 
 
 
 
 
 
 
 
 
Bipolar disorder 
 
 Twin studies suggest that the relationship between 
lifetime risks of smoking and major depression is 
solely due to shared genes that predispose to both 
conditions.
19
 
 
 Genetic and environmental neuropathological 
abnormalities in the hippocampus and prefrontal 
cortex can increase vulnerability to the rewarding 
effects of addictive drugs and to experiencing 
psychotic symptoms.
47
 
 Genes encoding nicotinic acetylcholine receptors, 
such as CHRNA2, CHRNB2, and CHRNA7, are 
associated with smoking traits in schizophrenia and 
are found at genetic loci implicated in 
schizophrenia.
48
 
 
 Common genes (COMT, SLC6A3, and SLC6A4) 
and gene networks have been associated with both 
tobacco use and bipolar disorder.
50
 
 Epidemiological studies show that nicotine 
dependence and bipolar disorder predict each 
other’s development.51 
 Shared environmental factors, such as childhood 
adversity and use of alcohol and illicit drugs, 
predict the development of both smoking and 
bipolar disorder.
52
 
 A family study of smoking and major 
depression did not find an increased risk of 
smoking among relatives of the person with 
depression.
46
 
 
 Genes strongly associated with an increased 
risk of developing schizophrenia are not 
associated with nicotine dependence or 
number of cigarettes per day.
118
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Panel 1 Benefits and drawbacks of smoking bans in mental health facilities 
Benefits  
• Protection of patients from smoking-related harms 
• Opportunity to quit smoking under the care of professionals and with access to smoking cessation therapies 
• Protection of non-smokers from second-hand smoke 
• Improvement in mental health on stopping smoking 
• Possible reduction in doses of some antipsychotic medications (e.g., clozapine) 
• Prevention of relapse in patients, and staff , who have quit smoking 
Drawbacks  
• Infringement of the right to smoke for involuntary patients and long-term residents of psychiatric care facilities 
• Deterrent to seeking inpatient psychiatric treatment 
• Possibility of severe withdrawal symptoms mimicking exacerbation of mental illness 
• Some patients might leave the facility unaccompanied or discharge themselves early in order to smoke 
 
 
 
 
 Panel 2  Prioritising smokers with serious mental illness for assessing effectiveness of tobacco harm reduction approaches 
 Some people with serious mental illness might be deterred from quitting smoking because they believe that smoking alleviates their depression 
and attentional-cognitive deficits and reduces the adverse effects of antipsychotic drugs.
17,108,109 
They might receive little support and 
encouragement from mental health personnel to quit because of unfounded fears about destabilising their mental condition.
62
 
 Switching to non-smoked nicotine products could reduce the required dose of some antipsychotic medicines. The non-nicotine components of 
tobacco smoke increase the metabolism of some antipsychotic drugs, which means that smokers need higher drug doses to achieve optimum 
plasma levels.
110
 
 People with serious mental illness are more often exposed to social environments that promote heavy smoking—e.g., spending time with peers 
and family members who smoke tobacco. This situation makes abstinence difficult to maintain.
111
 
 Smokers with serious mental illness, especially those with psychotic illnesses, are often socioeconomically disadvantaged and spend a large 
proportion of their income on cigarettes. Access to low-cost or subsidised harm-reduction products would not only be beneficial for the health 
of these smokers, but also make more of their limited income available for living expenses. 
 People with serious mental illness struggle to quit smoking successfully because of their heavy dependence on nicotine.57 Previous failed quit 
attempts could reduce confidence in making future attempts.
112,113 
This pattern can expose them to smoking for much longer than other 
smokers in the general population. Tobacco harm reduction options used as an interim step towards quitting could reduce tobacco-related 
harms sooner and encourage quitting. 
 Tobacco harm reduction for smokers with serious mental illness would satisfy important bioethical principles of beneficence (doing good), 
non-malefi cence (protecting from harm), autonomy (respecting individual freedoms), and justice (fairness and equality).
114
 Tobacco harm 
reduction also reduces some of the ethical concerns about enforced cessation in smoke-free mental health facilities if residents are permitted to 
use non-smoked nicotine products.  
  
 
Panel 3  Benefits and drawbacks of using e-cigarettes for tobacco harm reduction 
Benefits  
 A cleaner source of nicotine than cigarettes when used for self-medication 
 More economical than cigarettes in the long term 
 Provides the sociobehavioural aspects of smoking on Quitting 
 Can result in smoking cessation or reduction because of diminished addiction potential of nicotine in the absence of any monoamine oxidase 
inhibitors present in cigarette smoke 
Drawbacks 
 Limited research on the harms or benefit  of long-term use 
 Initially an e-cigarette kit costs more than a pack of cigarettes 
 People with severe mental illness might find some e-cigarettes difficult to use 
 
 
 
 
 
 Table 2  Interventional studies for smoking cessation in people with severe mental illness 
Title of the study Trial 
registry 
number 
Psychiatric 
condition 
Interventions Completion date Status 
Smoking Cessation for 
Depression and Anxiety 
Treatment 
NCT020
02858 
Depression and 
anxiety 
Nicotine Patch, Depression 
and Anxiety Smoking 
Cessation Treatment and 
Educational-Support 
Psychotherapy 
May 2016 Recruiting 
Decision Support for 
Smoking Cessation in 
Young Adults With Severe 
Mental Illness 
NCT017
79440 
Severe mental 
illness 
Electronic decision support 
system and placebo 
December 2015 Active, not recruiting 
Effects of Varenicline on 
Smoking Lapse in 
Smokers With and 
Without Schizophrenia 
NCT018
50953 
Schizophrenia Varenicline and Placebo May 2015 Completed 
Trial of Integrated 
Smoking Cessation, 
Exercise and Weight 
Management in Serious 
Mental Illness: TRIUMPH 
NCT024
24188 
Serious mental 
illness 
TRIUMPH Intervention June 2019 Not yet recruiting 
Smoking Cessation for 
Depressed Smokers 
NCT004
94728 
Major 
Depression 
Smoking Cessation 
Treatment, Nicotine 
Replacement Therapy and 
Cognitive Behavioural 
Analysis System of 
December 2016 Active, not recruiting 
Psychotherapy (CBASP) 
Effects of rTMS on 
Cigarette Smoking and 
Cognition in 
Schizophrenia 
NCT015
23730 
Schizophrenia Repetitive Transcranial 
Magnetic Stimulation 
(rTMS) and Sham Repetitive 
Transcranial Stimulation 
(rTMS) 
September 2015 completed 
Behavioural Activation 
and Varenicline for 
Smoking Cessation in 
Depressed Smokers 
NCT023
78714 
Depression Varenicline; behavioural 
activation for smoking 
cessation (BASC) and 
Standard treatment 
August 2020 Recruiting 
Novel Smoking Cessation 
Drug for Schizophrenia 
NCT022
30384 
Schizophrenia A novel drug and a placebo December 2016 Recruiting 
Study Evaluating The 
Safety And Efficacy Of 
Varenicline and Bupropion 
For Smoking Cessation In 
Subjects With And 
Without A History Of 
Psychiatric 
Disorders(EAGLES) 
NCT014
56936 
With and 
without 
psychiatric 
disorders 
Placebo, varenicline, 
bupropion hydrochloride and 
Nicotine Replacement 
Therapy Patch 
January 2015 
 
Completed 
Mobile Health Technology 
to Enhance Abstinence in 
Smokers With 
Schizophrenia 
NCT024
20015 
Schizophrenia Nicotine replacement 
therapy, Bupropion, 
cognitive-behavioural 
smoking cessation 
counselling, Mobile 
Contingency Management, 
Stay Quit Coach 
(smartphone application), 
SMS text messaging 
March 2018 Not yet recruiting 
Effects of Deep Breathing, 
Self-Help Book in 
Cigarette Consumption, 
Anxiety, Depression and 
Motivation to Stop 
Smoking 
NCT026
93561 
Anxiety and 
depression 
Deep Breathing Exercises 
and Self-Help Book 
August 2016 Recruiting 
Smoking Cessation 
Following Psychiatric 
Hospitalization 
NCT022
04956 
Severe mental 
illness 
Extended Care and Brief 
Education 
June 2019 Not yet recruiting 
Electronic Cigarettes in 
Smokers With Mental 
Illness 
NCT022
12041 
Schizophrenia, 
Schizophrenifor
m Disorder, 
Bipolar 
Disorder 
Disposable electronic 
cigarette s 
June 2016 Not yet recruiting 
Telephone-based Smoking 
Cessation 
NCT025
00589 
Depression Behavioural mood 
management and Health 
education 
June 2019 Not yet recruiting 
Smoking Cessation And 
Reduction in Depression 
NCT021
24187 
Depression Ecig containing 24 mg 
nicotine, Ecig containing 
0mg nicotine and Nicotine 
free inhalator 
December 2017 Not yet recruiting 
Acute Effects of Exercise 
in Smokers With 
Schizophrenia 
NCT016
35075 
Schizophrenia Exercise and passive control January 2015 Completed 
Transcranial Direct 
Current Stimulation 
(tDCS) As A Treatment 
For Cigarette Craving and 
Cognitive Deficits in 
Schizophrenic 
NCT021
28919 
Schizophrenia Device: tDCS December 2017 Recruiting 
Randomized Controlled 
Trial (RCT) of a 
Motivational Decision 
Support System 
NCT020
86162 
 
Schizophrenia Web-based motivational 
decision support system; and 
NCI (national cancer 
institute) Education 
March 2017 Recruiting 
Vigorous Exercise for 
Depressed Smokers 
NCT018
60924 
Depression Exercise and health 
education 
 
December 2015 Completed 
Exercise for Depressed 
Smokers 
NCT020
86149 
Depression Aerobic Exercise and Health 
Education 
September 2018 Recruiting 
Nicotine Receptor Density 
& Response to Nicotine 
Patch: Pt 2 Extended 
Treatment 
NCT026
76375 
Schizophrenia Standard therapy of Nicotine 
patch or bupropion and 
extended treatment with 
combination drugs with and 
without home visits and 
phone calls. 
February 2017 Active , not recruiting 
Effects of Varenicline on 
Plasticity in Schizophrenia 
NCT019
34023 
Schizophrenia Varenicline and Placebo 
 
August 2015 Completed 
Efficacy of N-Acetyl-
Cysteine in Bipolar 
Disorder and Tobacco Use 
Disorder 
NCT022
52341 
Bipolar disorder Dietary Supplement: N-
Acetyl-Cysteine 
September 2015 Enrolling by invitation 
Very Low Nicotine 
Cigarettes in Smokers 
With Schizophrenia 
NCT020
19459 
Schizophrenia Very low nicotine content 
cigarettes and standard 
nicotine content cigarettes 
August 2018 recruiting 
Contingency Management, 
Quitting Smoking, and 
ADHD 
NCT022
66784 
ADHD Contingency Management 
(CM); Transdermal nicotine 
skin patches (i.e. Habitrol) 
and Supportive Counselling 
October 2019 Recruiting 
Behavioural Activation for 
Smoking Cessation in 
NCT019
47725 
PTSD Nicotine patch, Nicotine 
gum or nicotine lozenge, 
September 2018 Recruiting 
Veterans With PTSD Standard Smoking Cessation 
Therapy, Health and 
Smoking Education, 
Behavioral Activation 
Treatment 
CPT and Smoking 
Cessation 
NCT019
01848 
PTSD Cognitive Processing 
Therapy (CPT), Bupropion, 
nicotine replacement therapy 
(NRT), Integrated Care for 
Smoking Cessation (ICSC), 
smokefreeVET program 
April 2018 Recruiting 
Integrated PTSD and 
Smoking Treatment 
NCT019
88935 
PTSD Prolonged Exposure and 
Smoking Cessation 
counselling 
June 2018 Recruiting 
Behavioural Activation for 
Smoking Cessation in 
PTSD 
NCT019
95123 
PTSD Behavioural Activation 
Therapy, Health and 
Smoking Education and 
Standard Smoking Cessation 
Therapy 
December 2018 Recruiting 
Improving Functional 
Outcomes of Veterans 
With PTSD and Tobacco 
Dependence 
NCT025
76899 
PTSD Acceptance and 
Commitment Therapy for 
PTSD and Tobacco Use; and 
Freedom From Smoking 
program 
August 2017 Recruiting 
 
